Tag Archives: Insulin Resistance

More adults living with type 1 diabetes are now developing obesity, insulin resistance, hypertension, and metabolic complications once linked mainly to type 2 diabetes. This growing overlap, often called double diabetes, is becoming a major concern for clinicians and patients alike. While insulin therapy remains essential for type 1 diabetes …

Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults. While metformin has long served as the standard first-line therapy, many clinicians are now reconsidering whether a “metformin-first and wait” strategy is enough for this higher-risk population. As research continues …

Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose …

Diabetes screening has improved over the last two decades, yet many patients still fall through the cracks. While clinicians often rely on traditional risk models that focus on obesity, age, family history, and sedentary lifestyle, not every patient with diabetes fits that familiar picture. As a result, many diabetes cases …

What if a medication designed to lower blood sugar could also help protect the brain? That question is driving growing interest among researchers studying the connection between GLP-1 drugs and Parkinson’s disease. Scientists are now exploring whether therapies originally developed for type 2 diabetes and obesity may influence inflammation, neuronal …

Why do some patients see impressive results with GLP-1 therapies while others barely respond? This question is becoming more relevant as clinicians encounter variability in outcomes. GLP-1 resistance is emerging as a possible explanation for suboptimal responses in certain individuals with diabetes. As a result, understanding how to identify and …

Why do some patients respond dramatically to GLP-1 therapies while others see little benefit? This question is becoming more relevant as GLP-1 receptor agonists gain widespread use in diabetes and weight management. Increasingly, clinicians are encountering cases of reduced response to GLP-1 therapies, where expected glycemic or weight outcomes fail …

The potential link between GLP-1 therapies and gout risk is gaining attention as clinicians look beyond glucose control to broader metabolic outcomes. Patients with obesity and type 2 diabetes often face a dual burden of hyperuricemia and gout, yet these conditions are not always addressed in treatment plans. Could medications …

What happens when a patient walks into your clinic and their diabetes simply doesn’t fit the usual mold? In many cases, clinicians rely on well-established categories like Type 1 or Type 2 diabetes. However, diagnosing atypical forms of diabetes is becoming increasingly important as more patients present with mixed or …

Interest in diabetes remission is growing in 2026, but is it realistic for everyone? As research evolves, clinicians are rethinking how and when to pursue remission as a treatment goal. While the idea of reversing type 2 diabetes is appealing, not every patient will benefit equally. This article explores the …